The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Poor survival rates of patients with tumors arising from or disseminating into the brain are attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (BBB) penetration of chemotherapies/targeted agents, and an intrinsic tumor radio-/chemo-resistance. Ataxia-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Adv
Main Authors: Durant, Stephen T., Zheng, Li, Wang, Yingchun, Chen, Kan, Zhang, Lingli, Zhang, Tianwei, Yang, Zhenfan, Riches, Lucy, Trinidad, Antonio G., Fok, Jacqueline H. L., Hunt, Tom, Pike, Kurt G., Wilson, Joanne, Smith, Aaron, Colclough, Nicola, Reddy, Venkatesh Pilla, Sykes, Andrew, Janefeldt, Annika, Johnström, Peter, Varnäs, Katarina, Takano, Akihiro, Ling, Stephanie, Orme, Jonathan, Stott, Jonathan, Roberts, Caroline, Barrett, Ian, Jones, Gemma, Roudier, Martine, Pierce, Andrew, Allen, Jasmine, Kahn, Jenna, Sule, Amrita, Karlin, Jeremy, Cronin, Anna, Chapman, Melissa, Valerie, Kristoffer, Illingworth, Ruth, Pass, Martin
Format: Artigo
Jezik:Inglês
Izdano: American Association for the Advancement of Science 2018
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6010333/
https://ncbi.nlm.nih.gov/pubmed/29938225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aat1719
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki